When combined with other treatments, the drug cetuximab - which works by slowing or stopping the growth of cancer cells - has been shown to extend survival in certain types of cancer, including metastatic colorectal cancers. Unfortunately, about 40 percent of colorectal cancer patients - specifically those who carry a mutated form of a gene called KRAS - do not respond to the drug...
More...
More...